Ozempic is now FDA-approved to reduce chronic kidney disease risks in diabetes patients. A Phase 3 trial showed Ozempic reduced kidney disease worsening by 24% and heart-related deaths by 5%.

The FDA has approved Ozempic to help lower chronic kidney disease-related risks in people with type 2 diabetes. The findings of a recent clinica trial, funded by drugmaker Novo Nordisk, indicate ...

In this trial, which followed more than 3,500 people with type 2 diabetes and chronic kidney disease over an average of 3.4 years, people who took a weekly shot of semaglutide in addition to ...

EU regulator supports a label expansion of Novo Nordisk’s diabetes drug to reflect its potential to lower the risk of conditions related to kidney disease in adults with Type 2 diabetes.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated with ...

Often called a wonder drug for type 2 diabetes and obesity, semaglutide — the active ingredient in Ozempic and Wegovy — may significantly improve kidney function in people with diabetes who ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type ...

(CNN) — Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks associated ...

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

It also reduced the risk of kidney failure and cut the risk of death from heart disease by about 5% in adults with both type 2 diabetes and chronic kidney disease, the company said in a news release.

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the US Food and Drug Administration to reduce certain risks ...